Lisata Therapeutics (NASDAQ:LSTA) Shares Up 1.4%

Lisata Therapeutics, Inc. (NASDAQ:LSTA)’s stock price shot up 1.4% on Friday . The company traded as high as $2.37 and last traded at $2.14. 25,306 shares changed hands during trading, an increase of 32% from the average session volume of 19,230 shares. The stock had previously closed at $2.11.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a “buy” rating and set a $15.00 target price on shares of Lisata Therapeutics in a research report on Tuesday, August 15th.

Lisata Therapeutics Price Performance

The company’s 50-day simple moving average is $3.00 and its 200 day simple moving average is $3.34. The firm has a market cap of $17.42 million, a P/E ratio of -0.22 and a beta of 1.24.

Lisata Therapeutics (NASDAQ:LSTA) last released its quarterly earnings data on Monday, August 14th. The company reported ($0.50) EPS for the quarter, beating the consensus estimate of ($0.70) by $0.20. Analysts anticipate that Lisata Therapeutics, Inc. will post -3.27 EPS for the current fiscal year.

Hedge Funds Weigh In On Lisata Therapeutics

Several institutional investors have recently bought and sold shares of the business. Citadel Advisors LLC bought a new position in Lisata Therapeutics during the second quarter valued at $64,000. BML Capital Management LLC purchased a new stake in shares of Lisata Therapeutics in the fourth quarter valued at $617,000. State Street Corp purchased a new stake in shares of Lisata Therapeutics in the third quarter valued at $66,000. Vanguard Group Inc. purchased a new stake in shares of Lisata Therapeutics in the third quarter valued at $817,000. Finally, BlackRock Inc. purchased a new stake in shares of Lisata Therapeutics in the third quarter valued at $263,000. Institutional investors own 8.36% of the company’s stock.

About Lisata Therapeutics

Lisata Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 1b/2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; HONEDRA, a recipient of SAKIGAKE designation critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and LSTA201, a CD34+ cell therapy for the treatment of chronic kidney disease.